Zealand Pharma reports positive phase III results against congenital hyperinsulinism

On Thursday, Zealand Pharma has announced positive topline results from a phase III trial of dasiglucagon, a treatment for congenital hyperinsulinism (CHI), the firm reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma sells insulin pump to Mannkind Corporation
For subscribers
Zealand Pharma rescue pen books USD 0.6m revenue in Q1
For subscribers